Alk-Abello AS (OCSE:ALK B) Total Liabilities : kr2,512 Mil (As of Mar. 2025)

View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Total Liabilities?

Alk-Abello AS's Total Liabilities for the quarter that ended in Mar. 2025 was kr2,512 Mil.

Alk-Abello AS's quarterly Total Liabilities increased from Sep. 2024 (kr2,063.00 Mil) to Dec. 2024 (kr2,873.00 Mil) but then declined from Dec. 2024 (kr2,873.00 Mil) to Mar. 2025 (kr2,512.00 Mil).

Alk-Abello AS's annual Total Liabilities declined from Dec. 2022 (kr2,320.00 Mil) to Dec. 2023 (kr2,279.00 Mil) but then increased from Dec. 2023 (kr2,279.00 Mil) to Dec. 2024 (kr2,873.00 Mil).

Alk-Abello AS Total Liabilities Historical Data

The historical data trend for Alk-Abello AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Total Liabilities Chart

Alk-Abello AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2,410.00

2,350.00

2,320.00

2,279.00

2,873.00

Alk-Abello AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															2,094.00	2,126.00	2,063.00	2,873.00	2,512.00

Alk-Abello AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alk-Abello AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1949	+	(451	+	49
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	251	+	173)
	=	2,873

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	8246	-	5373
	=	2,873

Alk-Abello AS's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1604	+	(434	+	48
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	253	+	173)
	=	2,512

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	8188	-	5676
	=	2,512

Alk-Abello AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALKBc:UK 0OIR:UK 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines